Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety and efficacy of repeated intravenous infusions of EMZ702 in combination with pegylated interferon and ribavirin in patients with chronic hepatitis C genotype 1.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: OPKO Health, Inc.; Transition Therapeutics
• Treatments: Interferons; Ribavirin

Criteria

Inclusion Criteria:

• Hepatitis C virus (HCV) genotype 1

• Previous therapy with pegylated interferon and ribavirin

• Documented previous treatment failure

Exclusion Criteria:

• Hepatic dysfunction

• Coinfection with hepatitis B or HIV

• Other unrelated liver diseases

• Liver cancer